Cefuroxime Axetil
drugOn this page
Also known as CCI 15641CCI-15641CeftinCefuraxCefuroxime (as axetil)CepazineCetoxilCurocefElobactNovadorNovocefNSC-758677OraximZinatZinnatCefuroxime-axetilCEFUROXIME AND AXETIL
Summary
Cefuroxime Axetil (CHEMBL1095930) is an approved small molecule; indicated across 9 conditions including sinusitis and urinary tract infection.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 9 conditions
- Clinical trials: 3
- Chemistry: 510.5 Da · C20H22N4O10S
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1095930 |
| Name | Cefuroxime Axetil |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 6321416 |
| Molecular formula | C20H22N4O10S |
| Molecular weight | 510.5 |
| InChIKey | KEJCWVGMRLCZQQ-YJBYXUATSA-N |
SMILES: CC(OC(=O)C)OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)/C(=N\OC)/C3=CC=CO3)COC(=O)N
IUPAC name: 1-acetyloxyethyl (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
Also known as: CCI 15641, CCI-15641, Ceftin, Cefurax, Cefuroxime (as axetil), Cefuroxime axetil, Cepazine, Cetoxil, Curocef, Elobact, Novador, Novocef
Patent coverage: 160 distinct patent families (237 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: ATP-binding cassette sub-family C member 4, 3’,5’-cyclic-AMP phosphodiesterase 4A.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| PDE4A | 5.79 | AC50 | 1610 | nM | CHEMBL_ACT_25207394 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (8 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| sinusitis | 4 | MONDO:0005961 | EFO:0007486 |
| urinary tract infection | 4 | MONDO:0100338 | EFO:0003103 |
| otitis media | 4 | MONDO:0005441 | EFO:0004992 |
| chronic bronchitis | 4 | MONDO:0005607 | EFO:0006505 |
| maxillary sinusitis | 4 | MONDO:0005842 | EFO:0007361 |
| tonsillitis | 4 | MONDO:0001039 | HP:0011110 |
| pharyngitis | 4 | MONDO:0002258 | MONDO:0002258 |
| osteomyelitis | 0 | MONDO:0005246 | EFO:0003102 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 3.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 2 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06527560 | PHASE4 | RECRUITING | Clinical Trial Comparing Oral Versus Intravenous Cefuroxime in Pregnant Women with Pyelonephritis |
| NCT01518192 | PHASE4 | COMPLETED | Comparison of Doxycycline and Cefuroxime Axetil for Treatment of Erythema Migrans: Clinical and Microbiological Outcome |
| NCT00000752 | PHASE2 | WITHDRAWN | Preventing Frequent Sinus Infections in HIV-Infected Patients |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).